Share This Author
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipILimumab monotherapy.
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
- Xiaoxian Li, M. Lewis, Jenny C. Chang
- Medicine, BiologyJournal of the National Cancer Institute
- 7 May 2008
These studies provide clinical evidence for a subpopulation of chemotherapy-resistant breast cancer-initiating cells and, in combination with conventional therapy, specific pathway inhibitors may provide a therapeutic strategy for eliminating these cells to decrease recurrence and improve long-term survival.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma, and the median overall survival in this study with a long follow-up was approximately 16 months.
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- C. Creighton, Xiaoxian Li, Jenny C. Chang
- Biology, MedicineProceedings of the National Academy of Sciences
- 18 August 2009
Supporting evidence is provided that the residual breast tumor cell populations surviving after conventional treatment may be enriched for subpopulations of cells with both tumor-initiating and mesenchymal features.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
- Kevin B. Kim, R. Kefford, K. Lewis
- Medicine, BiologyJournal of clinical oncology : official journal…
- 1 February 2013
The response rate for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma, and minimal clinical activity was observed as sequential therapy in patients previously treated with a BRAF inhibitor suggest that BRAf-inhibitor resistance mechanisms likely confer resistance to MEK- inhibitor monotherapy.
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival
- D. Bogunovic, D. O’Neill, N. Bhardwaj
- Medicine, BiologyProceedings of the National Academy of Sciences
- 1 December 2009
An immune response gene expression signature and presence of TILs and CD3+ cells signify immune surveillance as a mechanism for prolonged survival in these patients and indicate improved patient subcategorization beyond current TNM staging.
KIT as a therapeutic target in metastatic melanoma.
Among patients with advanced melanoma harboring KIT alterations, treatment with imatinib mesylate results in significant clinical responses in a subset of patients, indicating positive selection for the mutated allele.
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.
Serially passaged xenografts show biologic consistency with the tumor of origin, are phenotypically stable across multiple transplant generations at the histologic, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses as those observed clinically.